Elotuzumab in Combination with Pomalidomide and Corticosteroids for Relapsed or Refractory Multiple Myeloma

被引：0
|
作者：
Sidiqi, Hasib [1 ]
McGregor, Scott [2 ]
Baker, Ross [2 ]
Carnley, Ben [2 ]
Radeski, Dejan [1 ]
Barraclough, Allison [1 ]
Augustson, Bradley [1 ]
机构：
[1] Sir Charles Gairdner Hosp, Perth, WA, Australia
[2] Perth Blood Inst, Perth, Australia
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2017年 / 17卷 / 01期
关键词：
D O I：
10.1016/j.clml.2017.03.151
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS-149
引用
收藏
页码：E83 / E84
页数：2
相关论文
共 50 条
  • [31] Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma
    Hoylman, Emily
    Brown, Anna
    Perissinotti, Anthony J.
    Marini, Bernard L.
    Pianko, Matthew
    Ye, Jing Christine
    Campagnaro, Erica
    Nachar, Victoria R.
    LEUKEMIA & LYMPHOMA, 2020, 61 (03) : 691 - 698
  • [32] FDA Drug Approval: Elotuzumab in Combination with Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
    Gormley, Nicole J.
    Ko, Chia-Wen
    Deisseroth, Albert
    Nie, Lei
    Kaminskas, Edvardas
    Kormanik, Natasha
    Goldberg, Kirsten B.
    Farrell, Ann T.
    Pazdur, Richard
    CLINICAL CANCER RESEARCH, 2017, 23 (22) : 6759 - 6763
  • [33] Elotuzumab in combination with bortezomib in patients with relapsed/refractory multiple myeloma: A phase I study.
    Jakubowiak, A. J.
    Benson, D. M., Jr.
    Bensinger, W.
    Siegel, D. S.
    Zimmerman, T. M.
    Mohrbacher, A.
    Richardson, P. G.
    Afar, D.
    Singhal, A. K.
    Anderson, K. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [34] Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma
    Mary H. Young
    Greg Pietz
    Elizabeth Whalen
    Wilbert Copeland
    Ethan Thompson
    Brian A. Fox
    Kathryn J. Newhall
    Scientific Reports, 11
  • [35] Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
    Dimopoulos, Meletios A.
    Dytfeld, Dominik
    Grosicki, Sebastian
    Moreau, Philippe
    Takezako, Naoki
    Hori, Mitsuo
    Leleu, Xavier
    LeBlanc, Richard
    Suzuki, Kenshi
    Raab, Marc S.
    Richardson, Paul G.
    McKiver, Mihaela Popa
    Jou, Ying-Ming
    Shelat, Suresh G.
    Robbins, Michael
    Rafferty, Brian
    San-Miguel, Jesus
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (19): : 1811 - 1822
  • [36] Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
    Chari, Ajai
    Suvannasankha, Attaya
    Fay, Joseph W.
    Arnulf, Bertrand
    Kaufman, Jonathan L.
    Ifthikharuddin, Jainulabdeen J.
    Weiss, Brendan M.
    Krishnan, Amrita
    Lentzsch, Suzanne
    Comenzo, Raymond
    Wang, Jianping
    Nottage, Kerri
    Chiu, Christopher
    Khokhar, Nushmia Z.
    Ahmadi, Tahamtan
    Lonial, Sagar
    BLOOD, 2017, 130 (08) : 974 - 981
  • [37] Elotuzumab and dexamethasone for relapsed or refractory multiple myeloma patients: A retrospective study
    Gross, Zachary
    Rahbari, Ashkon
    Wirtschafter, Eric
    Spektor, Tanya M.
    Udd, Kyle A.
    Bujarski, Sean
    Ghermezi, Michael
    Nosrati, Jason D.
    Vidisheva, Aleksandra
    Eades, Benjamin
    Cecchi, Gary
    Maluso, Tina
    Swift, Regina
    Berenson, James R.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2018, 100 (06) : 621 - 623
  • [38] Efficacy, safety, and cost of pomalidomide in relapsed and refractory multiple myeloma
    Gueneau, Pauline
    Chretien, Marie-Lorraine
    Cransac-Miet, Amelie
    Aho, Ludwig Serge
    Lafon, Ingrid
    Favennec, Camille
    Guy, Julien
    Caillot, Denis
    Boulin, Mathieu
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2018, 100 (05) : 518 - 525
  • [39] Immunomodulation by durvalumab and pomalidomide in patients with relapsed/refractory multiple myeloma
    Young, Mary H.
    Pietz, Greg
    Whalen, Elizabeth
    Copeland, Wilbert
    Thompson, Ethan
    Fox, Brian A.
    Newhall, Kathryn J.
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [40] Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
    Shah, Jatin
    Usmani, Saad
    Stadtmauer, Edward A.
    Rifkin, Robert M.
    Berenson, James R.
    Berdeja, Jesus G.
    Lyons, Roger M.
    Klippel, Zandra
    Chang, Yu-Lin
    Niesvizky, Ruben
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (09): : 570 - +
12345